KODIAK SCIENCES INC. Diluted Shares Outstanding (Weighted Average)
KODIAK SCIENCES INC. (KOD) reported Diluted Shares Outstanding (Weighted Average) of 62.63 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-08-13
- KODIAK SCIENCES INC. weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 62.63M shares, a 18.66% increase year-over-year.
- KODIAK SCIENCES INC. weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 61.86M shares, a 17.28% increase year-over-year.
- KODIAK SCIENCES INC. weighted average number of shares outstanding, diluted for the quarter ending 2025-12-31 was 54.45M shares, a 3.41% increase year-over-year.
- KODIAK SCIENCES INC. weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 52.86M shares, a 0.46% increase year-over-year.
- KODIAK SCIENCES INC. weighted average number of shares outstanding, diluted for fiscal 2025 was 53.21M shares, a 1.19% increase from fiscal 2024.
- KODIAK SCIENCES INC. weighted average number of shares outstanding, diluted for fiscal 2024 was 52.58M shares, a 0.32% increase from fiscal 2023.
- KODIAK SCIENCES INC. weighted average number of shares outstanding, diluted for fiscal 2023 was 52.41M shares, a 0.32% increase from fiscal 2022.
- KODIAK SCIENCES INC. weighted average number of shares outstanding, diluted for fiscal 2022 was 52.25M shares, a 0.89% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | 62.63M shares 10-Q · filed 2026-08-13 | 62.25M shares 10-Q · filed 2026-08-13 | 59.65M shares derived: average of 3 quarters · filed 2026-08-13 | 57.95M shares derived: average of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 61.86M shares 10-Q · filed 2026-05-07 | 58.15M shares derived: average of 2 quarters · filed 2026-05-07 | 56.39M shares derived: average of 3 quarters · filed 2026-05-07 | 55.49M shares derived: average of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | 54.45M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 53.65M shares derived: average of 2 quarters · filed 2026-03-31 | 53.36M shares derived: average of 3 quarters · filed 2026-08-13 | 53.21M shares 10-K · filed 2026-03-31 |
| 2025-09-30 | 52.86M shares 10-Q · filed 2025-11-13 | 52.82M shares derived: average of 2 quarters · filed 2026-08-13 | 52.80M shares 10-Q · filed 2025-11-13 | 52.76M shares derived: average of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | 52.78M shares 10-Q · filed 2026-08-13 | 52.76M shares 10-Q · filed 2026-08-13 | 52.73M shares derived: average of 3 quarters · filed 2026-08-13 | 52.70M shares derived: average of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | 52.75M shares 10-Q · filed 2026-05-07 | 52.70M shares derived: average of 2 quarters · filed 2026-05-07 | 52.67M shares derived: average of 3 quarters · filed 2026-05-07 | 52.64M shares derived: average of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | 52.65M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 52.63M shares derived: average of 2 quarters · filed 2026-03-31 | 52.61M shares derived: average of 3 quarters · filed 2026-03-31 | 52.58M shares 10-K · filed 2026-03-31 |
| 2024-09-30 | 52.62M shares 10-Q · filed 2025-11-13 | 52.59M shares derived: average of 2 quarters · filed 2025-11-13 | 52.56M shares 10-Q · filed 2025-11-13 | 52.54M shares derived: average of 4 quarters · filed 2026-03-31 |
| 2024-06-30 | 52.55M shares 10-Q · filed 2025-08-13 | 52.53M shares 10-Q · filed 2025-08-13 | 52.52M shares derived: average of 3 quarters · filed 2026-03-31 | 52.50M shares derived: average of 4 quarters · filed 2026-03-31 |
| 2024-03-31 | 52.51M shares 10-Q · filed 2025-05-14 | 52.50M shares derived: average of 2 quarters · filed 2026-03-31 | 52.48M shares derived: average of 3 quarters · filed 2026-03-31 | 52.46M shares derived: average of 4 quarters · filed 2026-03-31 |
| 2023-12-31 | 52.48M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 52.47M shares derived: average of 2 quarters · filed 2026-03-31 | 52.44M shares derived: average of 3 quarters · filed 2026-03-31 | 52.41M shares 10-K · filed 2026-03-31 |
| 2023-09-30 | 52.46M shares 10-Q · filed 2024-11-14 | 52.42M shares derived: average of 2 quarters · filed 2024-11-14 | 52.39M shares 10-Q · filed 2024-11-14 | 52.37M shares derived: average of 4 quarters · filed 2025-03-27 |
| 2023-06-30 | 52.38M shares 10-Q · filed 2024-08-14 | 52.36M shares 10-Q · filed 2024-08-14 | 52.34M shares derived: average of 3 quarters · filed 2025-03-27 | 52.33M shares derived: average of 4 quarters · filed 2025-03-27 |
| 2023-03-31 | 52.34M shares 10-Q · filed 2024-05-15 | 52.33M shares derived: average of 2 quarters · filed 2025-03-27 | 52.31M shares derived: average of 3 quarters · filed 2025-03-27 | 52.29M shares derived: average of 4 quarters · filed 2025-03-27 |
| 2022-12-31 | 52.32M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 52.30M shares derived: average of 2 quarters · filed 2025-03-27 | 52.27M shares derived: average of 3 quarters · filed 2025-03-27 | 52.25M shares 10-K · filed 2025-03-27 |
| 2022-09-30 | 52.29M shares 10-Q · filed 2023-11-14 | 52.25M shares derived: average of 2 quarters · filed 2023-11-14 | 52.23M shares 10-Q · filed 2023-11-14 | 52.17M shares derived: average of 4 quarters · filed 2024-03-28 |
| 2022-06-30 | 52.22M shares 10-Q · filed 2023-08-14 | 52.20M shares 10-Q · filed 2023-08-14 | 52.13M shares derived: average of 3 quarters · filed 2024-03-28 | 52.06M shares derived: average of 4 quarters · filed 2024-03-28 |
| 2022-03-31 | 52.17M shares 10-Q · filed 2023-05-15 | 52.08M shares derived: average of 2 quarters · filed 2024-03-28 | 52.01M shares derived: average of 3 quarters · filed 2024-03-28 | 51.90M shares derived: average of 4 quarters · filed 2024-03-28 |
| 2021-12-31 | 51.99M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | 51.93M shares derived: average of 2 quarters · filed 2024-03-28 | 51.81M shares derived: average of 3 quarters · filed 2024-03-28 | 51.79M shares 10-K · filed 2024-03-28 |
| 2021-09-30 | 51.88M shares 10-Q · filed 2022-11-09 | 51.72M shares derived: average of 2 quarters · filed 2022-11-09 | 51.72M shares 10-Q · filed 2022-11-09 | |
| 2021-06-30 | 51.57M shares 10-Q · filed 2022-08-09 | 51.64M shares 10-Q · filed 2022-08-09 | ||
| 2020-12-31 | 45.74M shares 10-K · filed 2023-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |